These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 1707657

  • 1. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets.
    Nishikawa K, Saito S, Morii T, Kato Y, Narita N, Ichijo M, Ohashi Y, Takeshita T, Sugamura K.
    Int Immunol; 1990; 2(6):481-6. PubMed ID: 1707657
    [Abstract] [Full Text] [Related]

  • 2. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ, Nagler A, Lee F, Abrams J, Shatsky M, Thompson D.
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [Abstract] [Full Text] [Related]

  • 3. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J.
    Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
    [Abstract] [Full Text] [Related]

  • 4. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K, Saito S, Morii T, Hamada K, Ako H, Narita N, Ichijo M, Kurahayashi M, Sugamura K.
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [Abstract] [Full Text] [Related]

  • 5. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
    Hoshino S, Oshimi K, Teramura M, Mizoguchi H.
    Blood; 1991 Dec 15; 78(12):3232-40. PubMed ID: 1835892
    [Abstract] [Full Text] [Related]

  • 6. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R, Trentin L, Cerutti A, Enthammer C, Milani A, Franceschi T, Messina C, Cetto GL, Agostini C, Semenzato G.
    Cancer; 1994 Nov 01; 74(9):2562-9. PubMed ID: 7522954
    [Abstract] [Full Text] [Related]

  • 7. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.
    Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, Orengo A, Barbaresi M, Merli A, Ciccone E.
    J Exp Med; 1990 Dec 01; 172(6):1589-98. PubMed ID: 2147946
    [Abstract] [Full Text] [Related]

  • 8. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
    Ortaldo JR, Frey J, Takeshita T, Sugamura K.
    Eur Cytokine Netw; 1990 Dec 01; 1(1):27-34. PubMed ID: 2151685
    [Abstract] [Full Text] [Related]

  • 9. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C, Vitté-Mony I, Lang P, Pico J, Hercend T, Bertoglio J.
    Leukemia; 1992 May 01; 6(5):470-6. PubMed ID: 1375700
    [Abstract] [Full Text] [Related]

  • 10. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE, Fehniger TA, Caligiuri MA.
    Eur J Immunol; 1997 Feb 01; 27(2):354-60. PubMed ID: 9045904
    [Abstract] [Full Text] [Related]

  • 11. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE.
    Blood; 1992 Jun 15; 79(12):3239-44. PubMed ID: 1375847
    [Abstract] [Full Text] [Related]

  • 12. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
    Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM.
    J Exp Med; 1990 Oct 01; 172(4):1101-14. PubMed ID: 1698909
    [Abstract] [Full Text] [Related]

  • 13. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J, Broxmeyer HE.
    Cell Immunol; 1997 Sep 15; 180(2):132-42. PubMed ID: 9341743
    [Abstract] [Full Text] [Related]

  • 14. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
    Saito S, Morii T, Enomoto M, Sakakura S, Nishikawa K, Narita N, Ichijo M.
    Cell Immunol; 1993 Dec 15; 152(2):605-13. PubMed ID: 7504983
    [Abstract] [Full Text] [Related]

  • 15. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
    Zupo S, Azzoni L, Massara R, D'Amato A, Perussia B, Ferrarini M.
    J Clin Immunol; 1993 May 15; 13(3):228-36. PubMed ID: 7686565
    [Abstract] [Full Text] [Related]

  • 16. Identification and cellular distribution of the rat interleukin-2 receptor beta chain: induction of the IL-2R alpha- beta+ phenotype by major histocompatibility complex class I recognition during T cell development in vivo and by T cell receptor stimulation of CD4+8+ immature thymocytes in vitro.
    Park JH, Hanke T, Hünig T.
    Eur J Immunol; 1996 Oct 15; 26(10):2371-5. PubMed ID: 8898947
    [Abstract] [Full Text] [Related]

  • 17. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
    Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA.
    J Exp Med; 1994 Oct 01; 180(4):1395-403. PubMed ID: 7523571
    [Abstract] [Full Text] [Related]

  • 18. Activation of natural killer cells via the p75 interleukin 2 receptor.
    Phillips JH, Takeshita T, Sugamura K, Lanier LL.
    J Exp Med; 1989 Jul 01; 170(1):291-6. PubMed ID: 2787381
    [Abstract] [Full Text] [Related]

  • 19. Enhancement by stem cell factor of interleukin-2 (IL-2)-induced DNA synthesis in human decidual CD16- CD56bright natural killer cells mediated by increased expression of the IL-2 receptor alpha chain.
    Umekage H, Saito S, Morikawa H.
    J Reprod Immunol; 1998 Oct 01; 40(1):1-24. PubMed ID: 9862254
    [Abstract] [Full Text] [Related]

  • 20. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
    van de Griend RJ, Tax WJ, van Krimpen BA, Vreugdenhil RJ, Ronteltap CP, Bolhuis RL.
    J Immunol; 1987 Mar 01; 138(5):1627-33. PubMed ID: 2949018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.